Company intelligence / Profile preview
PharmEnable Therapeutics
Cambridge, England, United Kingdompharmenabletx.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
01
Overview
PharmEnable has developed a proprietary AI-driven platform to design novel small molecule drugs with biologic-like specificity. Their most advanced internal program focuses on preclinical development for ovarian cancer. The company also has a growing pipeline in oncology and neurology, with several co-discovery partnerships targeting hard-to-drug biological pathways. No clinical results have been published yet; all internal assets are preclinical.
- Therapeutic areas
- OtherOncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Sosei Heptaresmultiple undisclosed pharma/biotech partners for co-discovery projects
Beyond the preview
Go deeper on PharmEnable Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmEnable Therapeutics.